Shots:
- Elanco has granted Neurizon exclusive global rights to monepantel’s data package & related IP to develop & commercialize NUZ-001 & related compounds for the treatment, prevention, or palliation of ALS & other neurodegenerative diseases in humans
- As per the deal, Elanco will receive an upfront payment, development milestone payments of $9.75M for the initial & $5.2M for subsequent licensed products, indications, or presentations, ~$65M in sales milestones, & tiered single-digit royalties on global net sales
- The agreement also includes key terms on duration & pricing for the conclusion of a Supply Agreement, with a follow-up announcement on deal finalisation expected in H2’25
Ref: Prnewswire | Image: Neurizon Therapeutics | Press Release
Related News:- BioVersys Partners with Shionogi to Jointly Develop Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
